The board of directors of Simcere Pharmaceutical Group Limited announced that, on January 16, 2023, the New Drug Application of the innovative drug XIANNUOXIN (Simnotrelvir Tablets/Ritonavir Tablets (co-packaged)), which was jointly developed by the Group with Shanghai Institute of Materia Medica and Wuhan Institute of Virology, Chinese Academy of Sciences, has been accepted by the National Medical Products Administration of China under Special Examination and Approval of Drugs. XIANNUOXIN is intended to be used for the treatment of adults infected with mild to moderate COVID-19.